Additionally, a post-hoc analysis of the phase III ASCEND trial demonstrated that IPF patients with ANA, RF, and/or anti-CCP antibodies did not exhibit differences in their disease course compared to IPF patients without these autoantibodies [125]. The gene discussed is BTG3; the disease is idiopathic pulmonary fibrosis.